Antibiotic Incentives: FDA’s Woodcock Says LPAD Could Be Better Than Exclusivity, But Questions Remain
This article was originally published in The Pink Sheet Daily
Rep. Phil Gingrey, lead sponsor of the Generating Antibiotic Incentives Now Act, says industry still has questions about the proposed approval pathway for antibiotics treating life-threatening diseases, further clouding its prospects.
You may also be interested in...
A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.
FDASIA-mandated report indicates some trials underrepresented some racial groups, but the agency says those subsets may not be the proper groupings in the era of personalized medicine.
Robert Guidos returns to FDA from the Infectious Diseases Society of America as senior advisor in the CDER Immediate Office of the Center Director, although the job description seems to indicate a focus beyond antimicrobial issues.